Older patients with mantle cell lymphoma were more likely to have a maintained response with induction rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone followed by rituximab maintenance when compared against R-CHOP and interferon-alpha maintenance.
Oncology experts examine their patient population demographics and discuss the percentage of clear cell renal cell carcinoma patients who progress to receive third-line and subsequent…
The trial previously met its primary end point of progression-free survival, and the final overall survival analysis was recently presented at the 2024 World Conference…
Subcutaneous and intravenous forms of rituximab showed similar efficacy in patients with non-Hodgkin lymphoma.
Tebapivat, a novel pyruvate kinase activator, is being investigated for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.
The investigational agent certepetide has been granted FDA orphan drug designation for the treatment of patients with cholangiocarcinoma.
Panelists discuss how chronic graft-versus-host disease manifests across multiple organ systems and the diagnostic criteria used to identify and assess its various presentations.
Breast cancer diagnostics, therapeutics, and biomarker-driven therapy will be important focal points during the 22nd Annual School of Breast Oncology conference.
Pembrolizumab plus concurrent chemoradiotherapy demonstrated a higher progression-free survival rate than placebo plus concurrent chemoradiotherapy for patients with high-risk, locally advanced cervical cancer in the…
Response outcomes with liso-cel were consistent regardless of the presence of high-risk disease features in patients with relapsed/refractory chronic lymphocytic leukemia.
Ifinatamab deruxtecan, a novel antibody-drug conjugate, returned promising response rates at both dose levels evaluated among patients with small cell lung cancer.
